Biotinidase Deficiency: a Treatable Leukoencephalopathy

S. Grünewald; M. P. Champion; J. V. Leonard; J. Schaper; A. A. M. Morris

doi:10.1055/s-2004-821080

Neuropediatrics, Table of Contents

Neuropediatrics 2004; 35(4): 211-216
DOI: 10.1055/s-2004-821080

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Biotinidase Deficiency: a Treatable Leukoencephalopathy

S. Grünewald¹ ^, ² , M. P. Champion³ , J. V. Leonard² , J. Schaper⁴ , A. A. M. Morris² ^, ⁵

¹Children's Hospital, University Hospital Essen, Essen, Germany
²Metabolic Unit, Great Ormond Street Hospital for Children, London, UK
³Department of Paediatric Metabolic Medicine, Guy's Hospital, London, UK
⁴Radiology Department, Paediatric Radiology, University Hospital, Düsseldorf, Germany
⁵Willink Unit, Royal Manchester Children's Hospital, Manchester, UK

Abstract

The clinical history and the neuroradiological findings have been reviewed for 5 patients with biotinidase deficiency. Patients were diagnosed in the UK, where neonatal screening for this disorder is not done. The age at presentation ranged from 4 weeks to 5 months and the median interval between presentation and diagnosis was 5.5 months. The main abnormalities on cerebral imaging were leukoencephalopathy and widening of the ventricles and extra-cerebral CSF spaces. White matter abnormalities included delayed myelination but, in some patients, the increased signal was too great to be explained just by failure of myelination. Subtle subcortical changes were the only abnormality in one patient. Follow-up studies after treatment with biotin showed improved myelination; in one case, this was accompanied by normalisation of the CSF spaces but another patient showed progressive atrophy and cystic degeneration. Most of these patients have neurological sequelae. Biotinidase deficiency should be excluded in all patients with unexplained neurological problems. Neonatal screening provides the best chance of a good outcome.

Key words

Biotinidase deficiency - leukoencephalopathy - white matter changes - atrophy

Full Text

References

1 Bakker H D, Westra M, Overweg-Plandsoen W C, van Waveren G, Sillevis Smitt J H, Abeling N G. et al . Normalisation of severe cranial CT scan abnormalities after biotin in a case of biotinidase deficiency. Eur J Pediatr. 1994; 153 861-862
2 Baumgartner E R, Suormala T M, Wick H, Probst A, Blauenstein U, Bachmann C. et al . Biotinidase deficiency: a cause of subacute necrotizing encephalomyelopathy (Leigh syndrome). Report of a case with lethal outcome. Pediatr Res. 1989; 26 260-266
3 Bay C A, Berry G T, Glauser T A, Hayward J C, Wolf B, Sladky J T. et al . Reversible metabolic myopathy in biotinidase deficiency: its possible role in causing hypotonia. J Inherit Metab Dis. 1995; 18 701-704
4 Bousounis D P, Camfield P R, Wolf B. Reversal of brain atrophy with biotin treatment in biotinidase deficiency. Neuropediatrics. 1993; 24 214-217
5 Colamaria V, Burlina A B, Gaburro D, Pajno-Ferrara F, Saudubray J M, Merino R G. et al . Biotin-responsive infantile encephalopathy: EEG-polygraphic study of a case. Epilepsia. 1989; 30 573-578
6 Dionisi-Vici C, Bachmann C, Graziani M C, Sabetta G. Laryngeal stridor as a leading symptom in a biotinidase-deficient patient. J Inherit Metab Dis. 1988; 11 312-313
7 Haagerup A, Andersen J B, Blichfeldt S, Christensen M F. Biotinidase deficiency: two cases of very early presentation. Dev Med Child Neurol. 1997; 39 832-835
8 Heard G S, Secor McVoy J R, Wolf B. A screening method for biotinidase deficiency in newborns. Clin Chem. 1984; 30 125-127
9 Lara E B, Sansaricq C, Wolf B, Snyderman S E. Biotinidase deficiency in black children. J Pediatr. 1990; 116 750-752
10 Mardach R, Zempleni J, Wolf B, Cannon M J, Jennings M L, Cress S. et al . Biotin dependency due to a defect in biotin transport. J Clin Invest. 2002; 109 1617-1623
11 Mitchell G, Ogier H, Munnich A, Saudubray J M, Shirrer J, Charpentier C. et al . Neurological deterioration and lactic acidemia in biotinidase deficiency. A treatable condition mimicking Leigh's disease. Neuropediatrics. 1986; 17 129-131
12 Schulz P E, Weiner S P, Belmont J W, Fishman M A. Basal ganglia calcifications in a case of biotinidase deficiency. Neurology. 1988; 38 1326-1328
13 Wastell H, Dale G, Bartlett K. A sensitive fluorimetric rate assay for biotinidase using a new derivative of biotin, biotinyl-6-aminoquinoline. Anal Biochem. 1984; 140 69-73
14 Wastell H J, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. Arch Dis Child. 1988; 63 1244-1249
15 Wolf B, Hsia Y E, Sweetman L, Feldman G, Boychuk R B, Bart R D. et al . Multiple carboxylase deficiency: clinical and biochemical improvement following neonatal biotin treatment. Pediatrics. 1981; 68 113-118
16 Wolf B, Heard G S, Weissbecker K A, McVoy J R, Grier R E, Leshner R T. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol. 1985; 18 614-617
17 Wolf B, Heard G S. Biotinidase deficiency. Adv Pediatr. 1991; 38 1-21
18 Wolf B, Spencer R, Gleason T. Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. J Pediatr. 2002; 140 242-246
19 Wolf B. Disorders of biotin metabolism. Scriver CR, Beaudet AL, Valle D, Sly WS The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York; McGraw-Hill 2001: 3935-3962
20 van der Knaap M S, Valk J. Myelin and white matter. van der Knaap MS, Valk JN Magnetic Resonance of Myelin, Myelination and Myelin disorders. 2nd ed. Berlin; Springer 1995: 1-17

M.D. Stephanie Grünewald

Children's Hospital
University Hospital Essen

Hufelandstrasse 55

45122 Essen

Germany

Email: stephanie.gruenewald@uni-essen.de